Generated by AI
uniQure N.V. is a biopharmaceutical company focused on gene therapy for patients with severe genetic and other serious diseases. Its current portfolio includes HEMGENIX for hemophilia B and a pipeline of investigational therapies aimed at disorders such as Huntington’s disease, epilepsy, ALS, and Fabry disease. The company uses an adeno-associated virus (AAV) platform to develop one-time treatments designed to address the underlying cause of disease, with activities spanning research, development, manufacturing, and commercialization. Headquartered in Amsterdam, the Netherlands, uniQure serves the rare-disease and specialty therapeutic markets through both proprietary programs and selected partnerships.
WebsitePaasheuvelweg 25
Amsterdam, 1105 BP
Netherlands
The latest articles about QURE.
Analyst sees uniQure's (QURE) AMT-130 as a potential Huntington’s treatment: high-dose therapy slowed cUHDRS decline 80% at 3 years.
Summary of Nov 16's posts. Generated by AI.
Summary of Nov 4's posts. Generated by AI.
Summary of Mar 9's posts. Generated by AI.
Summary of Nov 2's posts. Generated by AI.
Investors talking about QURE also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.